Invited Commentary
May 2015

Evidence-Based Deprescribing of Statins in Patients With Advanced Illness

Author Affiliations
  • 1Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston
  • 2Division of Pharmacy, School of Medicine, Pharmacy and Health, Durham University, Durham, England

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2015;175(5):701-702. doi:10.1001/jamainternmed.2015.0328

Along with acknowledgment of the many advantages of statins, increasing focus has been placed on diminishing benefits and, in some cases, harms of this drug class when used in patients with limited life expectancy. Statins are prescribed for only preventive purposes, without symptomatic benefit to patients. As such, in some circumstances these agents, which have an estimated time until benefit of more than 2 years, depending on the indication and outcome, are not considered useful in patients with limited life expectancy and are even considered futile at the end of life.1

First Page Preview View Large
First page PDF preview
First page PDF preview